When acute myeloid leukemia cells with constitutively active Flt3 mutants, such as Flt3-ITD and Flt3(D835Y), are treated with statins (HMG-CoA reductase inhibitors), this reduces Akt activation by blocking receptor trafficking towards the PM25. Here, FLT3 is linked to acute myeloid leukemia.